Billion dollar bets: Denali+Biogen

  # # # # This week the biotech firm Denali Therapeutics made two major announcements regarding the development of their LRRK2 inhibitor program for Parkinson’s. First, the company revealed that they have signed an agreement with the pharmaceutical company Biogen to co-develop and co-commercialise small molecule inhibitors of LRRK2 for Parkinson’s. Second, Denali also … Continue reading Billion dollar bets: Denali+Biogen

Denali: Phase Ib clinical trial starts

  Biotech firm Denali announced the dosing of the first person in their Phase Ib clinical study of their experimental treatment for Parkinson’s called DNL201. DNL201 is an inhibitor of a Parkinson’s-associated protein called Leucine-rich repeat kinase 2 (LRRK2). In Parkinson’s, there is evidence that LRRK2 is over activate, and by inhibiting LRRK2 Denali is … Continue reading Denali: Phase Ib clinical trial starts

Inhibiting LRRK2: The Denali Phase I results

This week Denali Therapeutics released the results of a phase I clinical trial of their primary product, called DNL-201. DNL-201 is a LRRK2 inhibitor that the company is attempting to take to the clinic for Parkinson’s disease.  In today’s post we will look at what LRRK2 is, how an inhibitor might help in Parkinson’s, and what … Continue reading Inhibiting LRRK2: The Denali Phase I results